Table 1 Clinical evaluation of DAO and the measures used in plan comparison.
Author | Year | Participant numbers | Measures used in plan evaluation |
|---|---|---|---|
Van Asselen et al. [20] | 2006 | 12 breast cancer patients | • V95 & V105 of TV • D99 & DD01 to measure homogeneity within TV • Dmax to heart • Mean dose of both lungs |
Ahunbay EE et al. [19] | 2007 | 15 breast cancer patients | • Uniformity index • Global uniformity index • V20 lung • V25 heart |
Dobler et al. [22] | 2007 | 10 hypopharyngeal patients | • Absolute values for DVH points which violated the Dose volume objectives(DVO). • D95 & D5 of PTV • V95 & VV107 of PTV • Daverage • Dose homogeneity measured by (D5–D95)/Daverage • D50 to parotid gland • Dmax spinal cord |
Jones S et al. [21] | 2008 | 11 head and neck patients | • Composite objective value i.e. the weighted sum of al the objective values • Conformity index |
Ludlum E et al. [17] | 2008 | 5 prostate and 5 nasopharynx patients | • V95-tumouir coverage • Multiple defined endpoints for sensitive structures • Conformity index • Homogenity index • Delivery time |